RP11-529I10.4 Blocking Peptide
- Known as:
- RP11-529I10.4 Blocking Peptide
- Catalog number:
- 33r-5635
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- RP11-529I10.4 Blocking Peptide
Related products to: RP11-529I10.4 Blocking Peptide
Related articles to: RP11-529I10.4 Blocking Peptide
- Programmed cell death (PCD) is a fundamental and tightly regulated process that shapes plant development and ensures adaptive responses to environmental stimuli. This review provides an integrative overview of developmental PCD (dPCD) across vegetative and generative stages, from reproductive development and embryogenesis to vascular differentiation, aerenchyma formation, organ shaping, senescence, and abscission. We summarize current knowledge of the molecular, cellular, and physiological mechanisms governing dPCD, highlighting the coordinated roles of transcription factors, caspase-like proteases, reactive oxygen species, calcium signalling or phytohormones. The review further integrates insights from systematic embryology to illustrate how dPCD contributes to the diversity and stability of developmental patterns. Recent advances in omics technologies, single-cell analyses, live-cell imaging, and genome-editing tools are accelerating the identification of novel regulatory pathways and highlighting previously unrecognized layers of PCD control. Understanding developmental PCD is therefore essential not only for revealing the fundamental principles that govern plant growth and tissue patterning but also for enabling targeted manipulation of cell death pathways, with direct implications for crop improvement, stress resilience, and sustainable agriculture. - Source: PubMed
Publication date: 2026/08/04
Łuc JacekKwiatkowska MonikaSłomka AnetaSychta Klaudia - Programmed cell death (PCD) is a tightly controlled genetically regulated biological process, that controls morphogenic changes in any cell types during plant development or in response to environmental cues. Previously, significant progress has been made in identifying the key molecular players regulating the PCD process, how these components are integrated into context specific networks across developmental (dPCD) and environmentally induced PCD (ePCD) remains incompletely understood. This review summarizes the current understanding of PCD associated key molecular players, including calcium ions (Ca2+), reactive oxygen species (ROS), caspase-like proteases activity, transcriptional factors (TFs), and phytohormone signaling network and explicitly compares how their crosstalk orchestrate the initiation and execution of both dPCD and ePCD under biotic and abiotic stresses. A deeper mechanistic understanding of these interconnected signaling networks, and elucidating the crosstalk between development and stress induced PCD pathways might have significant implications in crop improvement as manipulating PCD processes can enhance crop disease resistance, optimize organ development and improve stress tolerance. - Source: PubMed
Publication date: 2026/03/10
Sarwar RehmanZhu Ke-MingZhang WeiLiang YuanxueTan Xiao-Li - Programmed cell death (PCD) is a fundamental biological process key to development, homeostasis and immune responses in all multicellular life forms. While the molecular regulation of diverse PCD forms have been extensively characterized in animals, the study of PCD in plants has recently gained momentum. Here, we highlight the functional roles of different PCD processes that occur as an integral part of plant development. We discuss the cellular and molecular frameworks governing the initiation and execution of PCD in plants, outline the challenges that have historically impeded progress in the field, and highlight the emerging technological innovations and plant models that are driving current discoveries. - Source: PubMed
Publication date: 2026/02/27
Pitsili EugeniaNowack Moritz K - About 40% of patients with pancreatic cancer (PC) are left untreated. Identification of the modifiable factors for opting out could increase the number eligible for treatment. We first assessed the completeness of registration. Next, we identified patients residing in the North Denmark Region, included 2023/24 in the Danish Pancreas Cancer Database (DPCD), registered as "no treatment". We supplemented register data with health record data, including reasons for opting out of treatment. Registration in DPCD was complete compared to the National Clinical Cancer Database, except for one patient. Six patients had other tumors. Of a total of 91 patients, 79% were >75 years old, 2/3 were in performance status (PS) > 2, more than half were socially or physically fragile, while 42% had significant comorbidity. Only 20% were referred to an oncologist. The median overall survival was 2 months, and the 1-year survival was 6%. Clinical stage and PS were prognostic in multivariable analysis. In 70%, poor PS was a reason for opting out of treatment, while 11% declined treatment without objective reasons. Poor PS, frailty, or patients' wishes explained 89% opting out of treatment. On a patient level, modifiable factors seem limited in this population. - Source: PubMed
Publication date: 2026/02/16
Ladekarl MortenStender Mogens Tornby - Parvalbumin (PV), a thermostable and digestion-resistant fish allergen, has been shown to retain its allergenic potential following traditional treatments, thus posing a persistent allergic risk. The study investigated the digestive kinetics and IgE immunoreactivity of Trachinotus ovatus PV, a major fish allergen, under different treatments (untreated; dense phase carbon dioxide (DPCD) treatment-15 MPa, 30 min, 50 °C; heat treatment), to evaluate its allergenic potential alterations. The analysis was conducted using a combination of techniques to assess the proteolytic stability and IgE-binding capacity of PV, including tris-tricine-SDS-PAGE, Western blot (WB), indirect enzyme-linked immunosorbent assay (ELISA), and free amino group quantification. The results demonstrated that pretreatment with DPCD significantly enhanced pepsin-mediated PV degradation, achieving hydrolysis and digestibility rates of 86.6 % and 86.4 %, respectively. The 90.9 % inhibition rate of IgE further suggested that the digested products were of reduced allergenicity. Furthermore, DPCD treatment accelerates the processes of α-chymotrypsin digestion. The results of the present study indicate that DPCD intervention improves gastrointestinal degradation of PV protein and attenuates the IgE reactivity of its breakdown products, suggesting its applicability as a novel non-thermal processing approach to mitigate allergenic risks in fish-allergic populations. - Source: PubMed
Publication date: 2025/09/08
Qiu HuiDuan WeiwenLiang RuirunHu WeichengKhan ImranLiu ShuchengWei Shuai